☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Calidi Biotherapeutics
Calidi Biotherapeutics and City of Hope Report the First Patient Dosing of CLD-101 in the P-I Trial for Recurrent High-Grade Gliom...
July 19, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.